October 31, 2017 12:33 PM EDTUpdated November 1, 10:16 AM
Pharma

As­traZeneca gets an ear­ly green light on BTK block­buster hope­ful Calquence

Brittany Meiling

Im­age: Pas­cal So­ri­ot AP Im­ages

As­traZeneca $AZN has re­ceived an ear­ly OK from reg­u­la­tors to sell its can­cer drug acal­abru­ti­nib, now un­der …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times